Yukimasa Makita

Yukimasa Makita

Auto-generated profile, based on publicly available information

Yukimasa Makita

Takeda-CiRA Joint Program, Fujisawa, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPeter Gee
Peter Gee
MLMandy S. Y. Lung
Mandy S. Y. Lung
YOYuya Okuzaki
Yuya Okuzaki
NSNoriko Sasakawa
Noriko Sasakawa
TITakahiro Iguchi
Takahiro Iguchi
AHAkitsu Hotta
Akitsu Hotta
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.

8 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EKEriya Kenjo
Eriya Kenjo
HHHiroyuki Hozumi
Hiroyuki Hozumi
YMYukimasa Makita
Yukimasa Makita
KIKumiko A. Iwabuchi
Kumiko A. Iwabuchi
NFNaoko Fujimoto
Naoko Fujimoto
AHAkitsu Hotta
Akitsu Hotta
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.

1 November 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YMYukimasa Makita
Yukimasa Makita
SMShumpei Murata
Shumpei Murata
YKYoshiki Katou
Yoshiki Katou
KKKuniko Kikuchi
Kuniko Kikuchi
HUHiroshi Uejima
Hiroshi Uejima
YKYuji Kawamata
Yuji Kawamata
Hepatocellular carcinoma (HCC) is still one of the major causes of cancer-related death. Kinetochore-associated protein 2 (KNTC2) is specifically upregulated in tumor tissues of HCC patients and recognized as a potential candidate target for the treatment of HCC. However, the relationship between KNTC2 and in vivo tumor growth of HCC is not yet fully understood. Here we encapsulated KNTC2 siRNAs into a lipid nanoparticle (LNP) and investigated their knockdown activity, target engagement marker, anti-tumor activity and hepatotoxicity in an orthotopic HCC model mice of Hep3B-luc cells. Single i.v. administration of KNTC2 siRNA-LNP specifically suppressed the expression levels of both human KNTC2 mRNA and mouse Kntc2 mRNA in tumor tissues. Phosphorylation levels of histone H3 (HH3) at serine 10 in tumor tissues were increased by KNTC2 siRNA-LNP. Repeated administration of KNTC2 siRNA-LNP (twice a week) specifically inhibited the growth of tumor tissues without increasing the plasma AST and ALT levels. Their growth inhibitory activities were consistent with knockdown activities. These data strongly indicated that KNTC2 is a promising target for the treatment of HCC and that phosphorylated HH3 at serine 10 is one of the target engagement markers for KNTC2.

1 May 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YMYo Muraki
Yo Muraki
YMYukimasa Makita
Yukimasa Makita
MYMidori Yamasaki
Midori Yamasaki
YAYuichiro Amano
Yuichiro Amano
TMTakanori Matsuo
Takanori Matsuo

22 April 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
YMYukimasa Makita
Yukimasa Makita
MAMakoto Asahina
Makoto Asahina
RFReiko Fujinawa
Reiko Fujinawa
HYHiroshi Yukitake
Hiroshi Yukitake
TSTadashi Suzuki
Tadashi Suzuki
NGLY1 deficiency is a genetic disease caused by biallelic mutations of the Ngly1 gene. Although epileptic seizure is one of the most severe symptoms in patients with NGLY1 deficiency, preclinical studies have not been conducted due to the lack of animal models for epileptic seizures in NGLY1 deficiency. Here, we observed the behaviors of male and female Ngly1−/− mice by video monitoring and found that these mice exhibit spontaneous seizure-like behaviors. Gene expression analyses and enzyme immunoassay revealed significant decreases in oxytocin, a well-known neuropeptide, in the hypothalamus of Ngly1−/− mice. Seizure-like behaviors in Ngly1−/− mice were transiently suppressed by a single intranasal administration of oxytocin. These findings suggest the therapeutic potential of oxytocin for epileptic seizure in patients with NGLY1 deficiency and contribute to the clarification of the disease mechanism.

29 January 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YMYukimasa Makita
Yukimasa Makita
MTMika Teratani
Mika Teratani
SMShumpei Murata
Shumpei Murata
YHYasutaka Hoashi
Yasutaka Hoashi
SMSatoru Matsumoto
Satoru Matsumoto
YKYuji Kawamata
Yuji Kawamata
It has been widely reported that patient-derived tumor xenografts (PDXs) are more similar to tumor tissues than conventional cancer cell lines. Kinetochore‑associated protein 2 (KNTC2) is known to be upregulated specifically in tumor tissues of cancer patients and is recognized as a potential target for cancer therapy. Previously, in vivo antitumor activities of KNTC2 short interfering RNA encapsulated into a lipid nanoparticle (KNTC2‑LNP) were reported in orthotopic hepatocellular carcinoma mouse models. However, it remains unclear whether KNTC2‑LNP exhibits antitumor activities against lung cancer PDXs. In the present study, the antitumor activities of KNTC2‑LNP were clarified in a three-dimensional culture system and a subcutaneous tumor model of lung cancer PDX, LC‑60, which was resistant to erlotinib. Growth inhibitory activities of KNTC2‑LNP were associated with knockdown activities. Furthermore, KNTC2‑LNP also exhibited in vivo antitumor activity against another lung cancer PDX, LC‑45, which was sensitive to erlotinib. These results suggest that KNTC2 is a promising target for patients with lung cancer.